Two CAIMed partner institutions, the L3S Research Center at Leibniz University Hannover and the University Medical Center Göttingen, have been awarded funding as partners in REGolution, a newly approved Marie Skłodowska-Curie Actions Doctoral Network (MSCA-DN) under the Horizon Europe programme. The project, coordinated by Universiteit Utrecht, will run for 48 months starting January 2027 and involves nine beneficiary institutions from seven European countries.

The Right Combination for a Complex Challenge

REGolution will train 14 doctoral candidates in advanced quantitative methods to support robust regulatory decision-making in drug development. The project requires precisely the combination of competencies that CAIMed has been building since its founding: AI-driven methodologies from L3S, and clinical research expertise from the University Medical Center Göttingen. Two institutions that have been working in close exchange within the CAIMed network.

The doctoral candidates will address methodological innovations for clinical trials, the analysis of real-world data for underrepresented populations, and transparent AI approaches to regulatory and Health Technology Assessment decision-making. All results will be made openly available as software, frameworks, and guidance materials for regulators, the scientific community, and patient stakeholders.

Cross-Institutional Collaboration as a Competitive Advantage

REGolution illustrates how CAIMed's model of connecting complementary research strengths across Lower Saxony can translate into impact at the European level. The consortium did not need to build this collaboration from scratch — it already existed. That is precisely what made the joint application compelling, and what will make the project's work effective.

Further consortium partners include the Paul-Ehrlich-Institut, the University of Oslo, the University of Copenhagen, Friedrich-Alexander-Universität Erlangen-Nürnberg, and AP-HP Paris Cité.